Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Interest Expenses (2022 - 2025)

Candel Therapeutics' Interest Expenses history spans 2 years, with the latest figure at $673000.0 for Q4 2023.

  • On a quarterly basis, Interest Expenses rose 16.44% to $673000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $2.6 million, a 69.39% increase, with the full-year FY2025 number at $2.1 million, up 1.39% from a year prior.
  • Interest Expenses hit $673000.0 in Q4 2023 for Candel Therapeutics, up from $669000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for CADL hit a ceiling of $673000.0 in Q4 2023 and a floor of $435000.0 in Q2 2022.